Login / Signup

Driving with Type 1 Diabetes: Real-World Evidence to Support Starting Glucose Level and Frequency of Monitoring During Journeys.

Steven TrawleyAmanda N StephensSybil A McAuleyProf Jane SpeightChristel HendrieckxSara VogrinMelissa H LeeBarbora PaldusLeon A BachMorton G BurtNeale D CohenPeter G ColmanElizabeth A DavisD Jane Holmes-WalkerAndrzej S JanuszewskiJoey KayeAnthony C KeechKavita KumareswaranRichard J MacIsaacRoland W McCallumCatriona M SimsStephen N StranksVijaya SundararajanGlenn M WardTimothy W JonesDavid Norman O'Neal
Published in: Diabetes technology & therapeutics (2022)
There is limited evidence supporting the recommendation that drivers with insulin-treated diabetes need to start journeys with glucose >90 mg/dL. Glucose levels of drivers with type 1 diabetes were monitored for 3 weeks using masked continuous glucose monitoring (CGM). Eighteen drivers (median [IQR] age 40 [35, 51] years; 11 men) undertook 475 trips (duration 15 [13, 21] min). Hypoglycemia did not occur in any trip starting with glucose >90 mg/dL (92%; n  = 436). Thirteen drivers recorded at least one trip (total n  = 39) starting with glucose <90 mg/dL. Among these, driving glucose was <70 mg/dL in five drivers (38%) during 10 trips (26%). Among five drivers (28%), a ≥ 36 mg/dL drop was observed within 20 min of starting their journey. Journey duration was positively associated with maximum glucose change. These findings support current guidelines to start driving with glucose >90 mg/dL, and to be aware that glucose levels may change significantly within 20 min. A CGM-based, in-vehicle display could provide glucose information and alerts that are compatible with safe driving. Clinical Trial Registration number: ACTRN12617000520336.
Keyphrases
  • blood glucose
  • type diabetes
  • clinical trial
  • healthcare
  • glycemic control
  • skeletal muscle
  • adipose tissue
  • insulin resistance
  • weight loss